Beijing Luzhu Biotechnology Co (HKSE:02480) Interest Expense: HK$-7.24 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$14.10
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co Interest Expense?

Beijing Luzhu Biotechnology Co HKSE:02480 24 Interest Expense is HK$-7.24 Mil as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Beijing Luzhu Biotechnology Co's interest expense for the six months ended in Dec. 2025 was HK$ -4.26 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-7.24 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Beijing Luzhu Biotechnology Co's Operating Income for the six months ended in Dec. 2025 was HK$ -76.83 Mil. Beijing Luzhu Biotechnology Co's Interest Expense for the six months ended in Dec. 2025 was HK$ -4.26 Mil. Beijing Luzhu Biotechnology Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Beijing Luzhu Biotechnology Co  (HKSE:02480) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beijing Luzhu Biotechnology Co's Interest Expense for the six months ended in Dec. 2025 was HK$-4.26 Mil. Its Operating Income for the six months ended in Dec. 2025 was HK$-76.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was HK$258.94 Mil.

Beijing Luzhu Biotechnology Co's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Beijing Luzhu Biotechnology Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Beijing Luzhu Biotechnology Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co Interest Expense Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.74 -0.81 -0.92 -0.82 -7.27

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only -0.50 -0.43 -0.39 -2.98 -4.26
HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-7.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of HK$-7.24 Mil mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a Interest Expense of HK$-7.24 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Beijing Luzhu Biotechnology Co and its competitors.
Is Beijing Luzhu Biotechnology Co's Interest Expense too high?
Beijing Luzhu Biotechnology Co's current Interest Expense is HK$-7.24 Mil. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's Interest Expense compare to VRTX and REGN?
Beijing Luzhu Biotechnology Co's Interest Expense of HK$-7.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Beijing Luzhu Biotechnology Co and its competitors. Beijing Luzhu Biotechnology Co's current Interest Expense is HK$-7.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current Interest Expense of HK$-7.24 Mil. The current Interest Expense is HK$-7.24 Mil. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current Interest Expense is HK$-7.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.10
Price